1 Theel ES, "The role of antibody testing for SARS-CoV-2 : is there one" 58 : e00797-, 2020
2 Maxwell LJ, "TNF-alpha inhibitors for ankylosing spondylitis" 18 : CD005468-, 2015
3 Galanis P, "Seroprevalence of SARS-CoV-2antibodies and associated factors in health care workers : a systematic review and metaanalysis" (S0195-6701) : 30522-, 2020
4 노지윤, "Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea" 대한의학회 35 (35): 1-6, 2020
5 Jääskeläinen AJ, "Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation" 129 : 104512-, 2020
6 Chen SY, "Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan" 9 : 2157-2168, 2020
7 Korea Disease Control and Prevention Agency (KDCA), "Management guidelines for coronavirus disease-19. Version 9"
8 Naaber P, "Evaluation of SARSCoV-2 IgG antibody response in PCR positive patients : comparison of nine tests in relation to clinical data" 15 : e0237548-, 2020
9 Manalac J, "Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and Euroimmune ELISA IgG/IgA assays in a clinical lab" 510 : 687-690, 2020
10 WHO, "Coronavirus disease (COVID-19) pandemic"
1 Theel ES, "The role of antibody testing for SARS-CoV-2 : is there one" 58 : e00797-, 2020
2 Maxwell LJ, "TNF-alpha inhibitors for ankylosing spondylitis" 18 : CD005468-, 2015
3 Galanis P, "Seroprevalence of SARS-CoV-2antibodies and associated factors in health care workers : a systematic review and metaanalysis" (S0195-6701) : 30522-, 2020
4 노지윤, "Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea" 대한의학회 35 (35): 1-6, 2020
5 Jääskeläinen AJ, "Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation" 129 : 104512-, 2020
6 Chen SY, "Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan" 9 : 2157-2168, 2020
7 Korea Disease Control and Prevention Agency (KDCA), "Management guidelines for coronavirus disease-19. Version 9"
8 Naaber P, "Evaluation of SARSCoV-2 IgG antibody response in PCR positive patients : comparison of nine tests in relation to clinical data" 15 : e0237548-, 2020
9 Manalac J, "Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and Euroimmune ELISA IgG/IgA assays in a clinical lab" 510 : 687-690, 2020
10 WHO, "Coronavirus disease (COVID-19) pandemic"
11 Korea Disease Control and Prevention Agency (KDCA), "Coronavirus disease (COVID-19)"
12 Pearce N, "Comparisons between countries are essential for the control of COVID-19" 47 : 1059-1062, 2020
13 Yoo JY, "Comparative analysis of COVID-19 guidelines from six countries: a qualitative study on the US, China, South Korea, the UK, Brazil, and Haiti" 20 : 1853-, 2020
14 Hu B, "Characteristics of SARS-CoV-2 and COVID-19" 6 : 1-14, 2020
15 Elslande JV, "Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs" 26 : 1557e1-1557e7, 2020